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H
augeberg et al recently published clinical decision rules
to identify patients with rheumatoid arthritis (RA) at
risk for osteoporosis.1 Included were patients treated
with glucocorticoids, a subject that has been for a long time
the interest of rheumatologists.2–4
For example, the Dutch Society for Rheumatology has
recently published guidelines for the prevention of glucocor-
ticoid induced osteoporosis (GIOP).5 This document was
prepared by a group of rheumatologists of the society and
other experts to mark the occasion of the publication of the
3rd Osteoporosis Guideline, (the ‘‘CBO consensus’’) which
was, in turn, prepared at the request of the Dutch authorities
by a multidisciplinary group who examined evidence based
medicine.6
Figure 1 is a stream diagram showing the diagnostic and
therapeutic steps in making decisions for the prevention of
GIOP.5 Factors that influence this decision include the dose of
glucocorticoids and the presence of other risk factors such as
age, sex, previous fracture, and bone mineral density (BMD).
The main message is that treatment with bisphosphonates
should be started immediately in patients at high risk (high
dose of glucocorticoids, prevalent fracture, postmenopausal
women, and elderly men).
The recommendations cover some uncertainties. Firstly,
it is unclear what is the threshold value of BMD below which
prevention is indicated if the intake of glucocorticoids is
,7.5 mg prednisone equivalents/day in the absence of
other risk factors. The CBO consensus suggested a T score
,22.5 or a Z score ,21.6 However, other groups have
suggested different thresholds. The UK consensus group
suggested a T score ,21.57 and the American College of
Rheumatology suggested a T score ,21.3 The main reason
for the absence of consensus is the uncertainty that the
risk for osteoporosis is increased in a low risk group treated
with low dose glucocorticoids, that fractures can be pre-
vented in this group and, perhaps most relevant, that the
fracture threshold is altered in GIOP.8 Indeed, bone loss
is limited in patients chronically treated with low dose
glucocorticoids if calcium and vitamin D supplements are
given.9
Secondly, it is still unclear if these patients should have an
x ray examination of the spine to document vertebral
deformities. Although only one in three vertebral deformities
is accompanied by acute symptoms of fractures, it has been
recently shown that non-clinically manifest vertebral defor-
mities also result in increased morbidity and an increased
risk for new fractures.10 11 Introducing a new risk factor is a
reason for increasing awareness: starting glucocorticoid
treatment should be accompanied by treatment with bisphos-
phonates in high risk patients and by dual energy x ray
absorptiometry (DXA) measurement in others.
Thirdly, specific risk factors of bone loss in conditions such
as RA were not considered. Accelerated bone loss has been
documented in patients with RA with high disease activity,12
immobility, and low body weight.13 However, no studies are
available on the prevention of osteoporosis in patients with
RA with these risk factors, and, thus, this information was
lacking in the guidelines.
Figure 1 Stream diagram for
osteoporosis prevention in GIOP.
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In conclusion, the guidelines on the prevention of GIOP,
which have been approved by the Dutch Society for
Rheumatology, should increase awareness about patients at
high risk. The publication by Haugeberg et al draws our
attention to patients with RA who are not treated with
glucocorticoids who perhaps also should be a target for
prevention of bone loss and osteoporosis. This proposal needs
to be fully explored in future studies. Thus, guidelines may
disclose not only our knowledge in specific clinical situations
but also may open up areas for new research.
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T
he treatment of patients with rheumatic diseases with
second line agents has expanded in the past three
decades. However, such drugs have been linked with the
development of malignancy, particularly in patients with
rheumatoid arthritis.1 Azathioprine is used to treat patients
with systemic lupus erythematosus (SLE) with renal disease,
or as a steroid-sparing agent.2 We have assessed the risk that
azathioprine treatment predisposes to the development of
malignancies and death in patients with SLE.
We carefully reviewed the case notes of 358 patients with
SLE receiving long term follow up in the Lupus Clinic at
University College London, between 1978 and 2002, and
assessed their treatment. Three hundred and twenty six
(91.1%) patients were female and 32 (8.9%) male. One
hundred and forty eight (41.3%) were treated at any time
with azathioprine, while 210 (58.7%) never used this second
line agent. The mean (SD) ages of the users and non-users
were similar (40.5 (12.7) v 45.3 (13.2), respectively, which is
not significant by x2 test with 95% confidence intervals). The
mean (SD) duration of azathioprine treatment was 3.8 (3.9)
years (minimum of 6 months and maximum of 18 years).
Most patients are alive (83.2%) and only a minority were lost
to follow up (3.1%). Forty nine (13.7%) of our patients have
died: 27/148 (18%) had received azathioprine and 22/210
(10%) had not. Eight of our patients prescribed azathioprine
developed a malignancy (none had a lymphoma), whereas 14
not given azathioprine have done so (three had lymphomas:
one non-Hodgkin and two Hodgkin). These differences are
not statistically significant (x2 test). However, the number of
deaths in the azathioprine group which is almost double
that in the other group does raise concerns, although it
may simply be identifying a subgroup with more serious
disease.
Table 1 shows the number of malignancies and death in
patients with SLE treated with azathioprine, according to the
duration of treatment.
Five of the patients who died were receiving azathioprine
for ,1 year, 10 for between 1 and 4 years, 11 for between 5
and 9 years, and 1 for .10 years. Five patients who
developed malignancy were receiving azathioprine for
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